Floatz logo

Shr-4602

Breast Neoplasm

Fudan UniversityPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

176 Active assets in the Breast Neoplasm cohort.

Asset / SponsorPhaseRating
Inno-206
Merck Sharp & Dohme LLC
Phase 4BB
EXEMESTANE
Fujian Cancer Hospital
Phase 4BB
Cyclophosphamide
Merck Sharp & Dohme LLC
Phase 4BB
TAMOXIFEN
Eli Lilly and Company
Phase 3BB
Docetaxel
Universitas Airlangga
Phase 4BB

View all 50 →

Same molecule, other indications

Shr-4602 is also rated in:

Hormone Receptor Positive TumorDormant
CCC
Indicative ·
53 / 100
View asset →
triple-negative breast carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
Hormone Receptor Negative TumorDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →